Metabolic syndrome and breast cancer: prevalence, treatment response, and prognosis

S Dong, Z Wang, K Shen, X Chen - Frontiers in oncology, 2021 - frontiersin.org
Metabolic syndrome is a type of multifactorial metabolic disease with the presence of at least
three factors: obesity, diabetes mellitus, low high-density lipoprotein, hypertriglyceridemia …

Is cholesterol a risk factor for breast cancer incidence and outcome?

CB Hassen, C Goupille, C Vigor, T Durand… - The Journal of Steroid …, 2023 - Elsevier
Cholesterol plays important roles in many physiological processes, including cell membrane
structure and function, hormone synthesis, and the regulation of cellular homeostasis. The …

[HTML][HTML] Pitavastatin induces autophagy-dependent ferroptosis in MDA-MB-231 cells via the mevalonate pathway

WJ Tang, D Xu, MX Liang, GQ Wo, WQ Chen, JH Tang… - Heliyon, 2024 - cell.com
Triple-negative breast cancer (TNBC) is more prone to recurrence and metastasis relative to
other subtypes of breast cancer, leading to an extremely poor prognosis. The increasing …

A high serum-free fatty acid level is associated with cancer

L Zhang, L Han, J He, J Lv, R Pan, T Lv - Journal of Cancer Research and …, 2020 - Springer
Purpose The objectives of this work were to investigate whether the serum-free fatty acid
(FFA) level is meaningful in cancer patients and its role in cancer diagnosis. Methods A total …

The impact of statin use and breast cancer recurrence-a retrospective study in Singapore

Y Sim, C Lim, N Phyu, KTB Tan, LST Chew… - Frontiers in …, 2022 - frontiersin.org
Introduction Statins, HMG-CoA reductase inhibitors, are commonly used cholesterol-
lowering medications which are also increasingly recognized to have anti-cancer properties …

Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study

OW Scott, S TinTin, S Harborg… - Breast Cancer Research …, 2023 - Springer
Purpose Statins are the most widely prescribed cholesterol lowering medications and have
been associated with both improved and unchanged breast cancer outcomes in previous …

[HTML][HTML] Mutant p53, the mevalonate pathway and the tumor microenvironment regulate tumor response to statin therapy

M Pereira, K Matuszewska, A Glogova, J Petrik - Cancers, 2022 - mdpi.com
Simple Summary For tumors to initiate and sustain rapid growth, they need to alter their
metabolic reprograming to support this growth. While many oncogenes upregulate …

Association between statin use and prognosis of breast cancer: A meta-analysis of cohort studies

H Lv, D Shi, M Fei, Y Chen, F **e, Z Wang… - Frontiers in …, 2020 - frontiersin.org
Background: Statin, a lipid-lowering drug, has been suggested to confer anticancer efficacy.
However, previous studies evaluating the association between statin use and prognosis in …

Concurrent use of statins in patients undergoing curative intent treatment for triple negative breast Cancer: A Systematic Review and Meta-Analysis

T McKechnie, Z Brown, O Lovrics, S Yang, T Kazi… - Clinical breast …, 2024 - Elsevier
Pre-clinical studies in triple negative breast cancer (TNBC) suggest that statins may inhibit
cell proliferation, promote cell-cycle arrest, induce apoptosis, change the tumor …

[HTML][HTML] Impact of statin use on cancer-specific mortality and recurrence: A meta-analysis of 60 observational studies

J Yang, C Li, Y Shen, H Zhou, Y Shao, W Zhu, Y Chen - Medicine, 2020 - journals.lww.com
Medicine Log in or Register Get new issue alertsGet alerts Secondary Logo Journal Logo
Advanced Search Toggle navigation Register Login Articles & Issues Browse by Specialty …